Financials Arecor Therapeutics plc

Equities

Market Closed - London S.E. Other stock markets 11:35:22 2024-12-13 am EST			5-day change	1st Jan Change
68.50 ^GBX	-10.46%		-10.46%	-62.47%

Nov. 18	Arecor Therapeutics names David Ellam as interim CFO	AN
Nov. 18	Arecor Therapeutics Names Interim CFO	MT

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	1.158	2.403	4.573	5.884	9.061	11.63
Change	-	-	107.51%	90.3%	28.66%	54%	28.32%
EBITDA ¹	-	-6.268	-10.29	-8.679	-7.506	-5.521	-3.38
Change	-	-	64.15%	-15.65%	13.51%	26.44%	38.78%
EBIT ¹	-	-6.439	-10.63	-9.175	-8.413	-6.341	-4.425
Change	-	-	65.09%	-13.69%	8.31%	24.63%	30.22%
Interest Paid	-	-0.507	-	-	-	-	-
Earnings before Tax (EBT) ¹	-	-6.945	-10.54	-8.901	-8.057	-5.64	-2.357
Change	-	-	51.79%	-15.57%	9.48%	30.01%	58.21%
Net income ¹	-2.752	-6.169	-9.26	-8.554	-8.032	-6.179	-
Change	-	124.13%	50.11%	-7.62%	6.1%	23.07%	100%
Announcement Date	7/1/21	4/25/22	4/20/23	5/16/24	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-18.3	-12.8	-6.75	-4.1	-0.8	2.63
Change	-	-	-169.95%	-152.73%	-160.72%	-119.51%	228.75%
Announcement Date	7/1/21	4/25/22	4/20/23	5/16/24	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2021	2022	2023	2024	2025	2026
CAPEX ¹	0.069	0.299	0.151	0.166	0.174	-
Change	-	333.33%	-49.5%	9.93%	4.82%	-100%
Free Cash Flow (FCF) ¹	-	-11.08	-5.992	-7.861	-2.746	-2.381
Change	-	-	-45.92%	31.19%	-65.07%	-13.3%
Announcement Date	4/25/22	4/20/23	5/16/24	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-	-	-541.28%	-428.17%	-189.79%	-127.58%	-60.94%	-29.07%
EBIT Margin (%)	-	-	-556.04%	-442.36%	-200.63%	-142.98%	-69.98%	-38.06%
EBT Margin (%)	-	-	-599.74%	-438.7%	-194.64%	-136.94%	-62.24%	-20.27%
Net margin (%)	-	-	-532.73%	-385.35%	-187.05%	-136.51%	-68.19%	-
FCF margin (%)	-	-	-	-461.05%	-131.03%	-133.6%	-30.31%	-20.48%
FCF / Net Income (%)	-	-	-	119.64%	70.05%	97.87%	44.44%	-
Profitability
ROA	-47.47%	-49.89%	-29.64%	-30.63%	-30.88%	-	-	-
ROE	-99.68%	-138.25%	-63.85%	-51.44%	-63.41%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-0.78x
Debt / Free cash flow	-	-	-	-	-	-	-	-1.11x
Capital Intensity
CAPEX / Current Assets (%)	-	-	5.96%	12.44%	3.3%	2.82%	1.92%	-
CAPEX / EBITDA (%)	-	-	-1.1%	-2.91%	-1.74%	-2.21%	-3.15%	-
CAPEX / FCF (%)	-	-	-	-2.7%	-2.52%	-2.11%	-6.34%	-
Items per share
Cash flow per share ¹	-	-	-0.2366	-0.3725	-0.1907	-	-	-
Change	-	-	-	57.44%	-48.81%	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	0.5701	0.3111	0.2161	0.00417	-0.1534
Change	-	-	-	-	-45.43%	-30.55%	-98.07%	-3,777.46%
EPS ¹	-	-1.02	-0.27	-0.32	-0.28	-0.3	-0.2	-
Change	-	-	-73.53%	18.52%	-12.5%	7.14%	-33.33%	-
Nbr of stocks (in thousands)	-	-	27,835	30,618	30,627	37,757	37,757	37,757
Announcement Date	-	7/1/21	4/25/22	4/20/23	5/16/24	-	-	-